Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: Relationship to angiotensin II signaling

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1963-1969

  Pagnin, Elisa ^a   Davis, Paul A ^b   Sartoria, Michelangelo ^a   Semplicini, Andrea ^a   Pessina, Achille C ^a   Calò, Lorenzo A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II signaling; Bartter's syndrome; Gitelman's syndrome; Hypertension; PAI 1; Rho kinase

Indexed keywords

ANGIOTENSIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE;

ADULT; ARTICLE; ATHEROGENESIS; BARTTER SYNDROME; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVATION; FEMALE; GENE FUNCTION; GITELMAN SYNDROME; HORMONAL REGULATION; HUMAN; HYPERTENSION; MALE; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR FIBROSIS; WESTERN BLOTTING;

EID: 5044227527     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00019     Document Type: Article

References (33)

1. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270:29051-29054.
2. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J; 15:2208-2216.
3. Fukata Y, Amano M, Kaibuki K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22:32-39.
4. Sward K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5:66-72.
5. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994.
6. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38:1307-1310.
7. Chitaley K, Weber D, Webb RC. RhoA/Rho-kinase, vascular changes and hypertension. Curr Hypertens Rep 2001; 3:139-144.
8. Aoki H, Izumo S, Sadoshima J. Angiotensin 11 activates RhoA in cardiac myocytes. A critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 1998; 82:666-676.
9. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000; 35:313-318.
10. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39:245-250.
11. Kim JH, Cho YS, Kim BC, Lee GS, Role of Rho GTPase in the endothelin-1 induced nuclear signaling. Biochem Biophys Res Commun 1997; 232:223-226.
12. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106:57-62.
13. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21:868-873.
14. Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol 2000; 278:H1744-H1750.
15. Calò L, Davis PA, Semplicini A. Control of vascular tone in the syndromes of Bartter and Gitelman. Crit Rev Clin Lab Sci 2000; 37:503-522.
16. Calo L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60:882-889.
17. Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61:353-354.
18. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative streas-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525.
19. Calo L, D'Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, et al. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72:570-573.
20. Di Virgilio F, Calò L, Cantaro S, Favaro S, Piccoli A, Borsatti A. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72:483-488.
21. Hebert SC. Bartter's syndrome. Curr Opin Nephrol Hypertens 2003; 12:527-532.
22. Calò L, Davis PA, Semplicini A. Bartter's/Gitelman's syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59:393-394.
23. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens 2002; 20:593-596.
24. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes Is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39:777-780.
25. Calò L, Scognamiglio R, Nistri S, Palisi M, Miorelli M, Zerbo F, et al. Evidence of myocardial dysfunction in Bartter's syndrome. Am J Nephrol 1997; 17:124-127.
26. 3- and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27:784-789.
27. Yoshida H, Kakuchi J, Yoshikawa N, Saruta T, Inagami T, Phillips JA 3rd, et al. Angiotensin II type 1 receptor gene abnormality in a patient with Bartter's syndrome. Kidney Int 1994; 46:1505-1509.
28. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997; 29:366-373.
29. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001; 37:1047-1052.
30. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5:155-164.
31. Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y, et al. Involvement of Rho-kinase pathway for Ang 11-induced plasminogen activator inhibitor gene expression and cardiovascular remodelling in hypertensive rats. J Pharmacol Exp Ther 2002; 301;459-466.
32. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, et al. Aldosterome mediates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58:1219-1227.
33. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, et al. Bleomicin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97:232-237.